Surrogate markers of tumoral angiogenesis

Citation
Gj. Byrne et Nj. Bundred, Surrogate markers of tumoral angiogenesis, INT J B MAR, 15(4), 2000, pp. 334-339
Citations number
44
Categorie Soggetti
Oncology
Journal title
INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS
ISSN journal
03936155 → ACNP
Volume
15
Issue
4
Year of publication
2000
Pages
334 - 339
Database
ISI
SICI code
0393-6155(200010/12)15:4<334:SMOTA>2.0.ZU;2-W
Abstract
Background: Angiogenesis is a prerequisite for tumor growth and metastasis. Vascular cell adhesion molecule-1 (VCAM-1) is expressed on endothelial cel ls as a result of vascular endothelial growth factor (VEGF) stimulation. Pu rpose: To determine if measurement in serum of VEGF or VCAM-1 provides an a ccurate measure of tumor angiogenesis. Methods: VCAM-1 and VEGF were measured in the serum of women with early and advanced breast cancer by ELISA. Levels were compared to levels of VCAM-1 and VEGF in women with normal breasts and levels of the endothelial glycopr otein von Willebrand factor. Levels of VEGF and VCAM-1 in women with early breast cancer were correlated with established clinicopathological prognost ic markers and intratumoral microvessel density (IMD). Results: In early breast cancer serum VCAM-1 correlated closely with the mi crovessel density in tumors (r=0.61, p<0.001). Women with lymph node-positi ve and high-grade tumors had higher levels of serum VCAM-1 than women with lymph node-negative and low-grade tumors. Serum VEGF demonstrated no correl ation with established prognostic features or IMD. Levels of VCAM-1 and VEG F were raised in women with advanced breast cancer. Conclusion: Serum VCAM-1 is a surrogate marker of angiogenesis in breast ca ncer and its measurement may help in the assessment of antiangiogenic drugs currently in phase II trials.